	/0	'' '	. 7		
Subs	titute for form 1449A/PTO		8		С
l	(_ OCT	192	007	Application Number	T
l			- 25/_	Filing Date	t
IN	FORMATION DIS	CLO	SURE	First Named Inventor	t
S	TATEMENT BY AF	PEI	CANT	Art Unit	Ť
l	(Use as many sheets as ne	cessar	y)	Examiner Name	Ť
Choot	1	of	3	Attorney Docket Number	t

ALD A

Complete if Known		
Application Number	10/588,409	
Filing Date	August 3, 2006	
First Named Inventor	Tidmarsh, George	
Art Unit	1624	
Examiner Name	Unassigned	
Attorney Docket Number	021305-004010US	

			U.S. PATENT DO	DCUMENTS	
Examiner Initials*	Cite No.1	Document Number  Number Kind Code <sup>2 (Finance)</sup>	Publication Date MM-DD-YYYY	Name of Palentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,489,302	12-03-2002	Wiessler et al.	
	AB	US-5,622,936	04-22-1997	Wiessler et al.	
	AC	US-5,464,826	11-07-1995	Grindey et al.	
	AD	US-4,808,614	02-28-1989	Hertel	
	ΑE	US-2005/0054708	03-10-2005	Michols et al.	
	AF	US-2004/0167079	08-26-2004	Tidmarsh	
	AG	US-2004/0136950	07-15-2004	Ni et al.	
	AH	US-60/910,403		Handisides et al.	
		•		· · · · · · · · · · · · · · · · · · ·	

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite			Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	т.		
initials.		Country Code <sup>3</sup>	Number*	Kind Code <sup>6</sup> (if known)		Applicant of Cited Document	or Relevant Figures Appear	T"	
	AI	wo	08/071955	A2	07-06-2006	Threshold Pharmaceuticals Inc.			
	AJ	wo	06/122227	A1	11-16-2006	Threshold Pharmaceuticals Inc.			
	AK	wo	07/035961	A1	03-29-2007	Threshold Pharmaceuticals Inc.			
								Г	
	I							П	

## ALL BEFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /B.S./

Examiner Signature	/Bahar Schmidtmann/	Da Co	ate onsidered	07/07/2011	

EXAMINER initial if reference considered, whether or not olation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicants unique citation designation number (optional). "Kind 573,1" For Japaness papert documents, the incidention of the keys of the region of the Emporer may proceed the senting number of the paper of the conformation of the Communication of the Emporer may be proceeded by senting interface of the conformation of the Communication of the Emporer may be proceeded by the applicant is to place a check mark here if Emplish indiagous promation is attached.

Substitute for	or form 1449B/PTO				Complete if Known
				Application Number	10/588,409
INFO	RMATION DIS	CLOS	URE	Filing Date	August 3, 2006
STAT	EMENT BY A	PPLIC	ANT	First Named Inventor	Tidmarsh, George
				Art Unit	1624
(	Use as many sheets as r	ecessary)		Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	021305-004010US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, dily and/or outurity where published.	T²
		ARANEO et al., "Biweekly Low-Dose Sequential Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (GFP): A	П
		Highly Active Novel Therapy for Metastatic Adenocarcinoma of the Exocrine Pancreas," Cancer Invest., 21(4):489-496 (2003).	
***************************************		BRIASOULIS et al., "Phase I Trial of 6-Hour Infusion of Glufosfamide, a New Alkylating Agent With Potentially	
		Enhanced Selectivity for Tumors That Overexpress Transmembrane Glucose Transporters: A Study of the European	1
	AM	Organization for Research and Treatment of Cancer Early Clinical Studies Group," <u>J. Clin Oncol.</u> , 18(20):3535-3544 (2000).	
		BURRIS et al., "Assessing Clinical Benefit in the Treatment of Pancreas Cancer: Gemcitabine Compared to 5-	_
	ÁN	Fluorouracil," <u>Eur. J. Cancer</u> , 33(Suppl 1):S18-S22 (1997).	니
		KOZUCH et al., "Irinotecan Combined with Gemcitabine, 5-Fluorouracil, Leucovorin, and Cisplatin (G-FLIP) is an	
	AO	Effective and Noncrossresistant Treatment for Chemotherapy Refractory Metastatic Pancreatic Cancer," <u>The Oncologist</u> , 6:488-495 (2001).	
	AP	NICULESCU-DUVAZ, I., "Glufosfamide (Baxter Oncology)," <u>Curr. Opin. Investig. Drugs</u> , 3(10):1527-1532 (2002).	
	I AQ	NOBLE et al., "Gemcitabine. A review of its Pharmacology and Clinical Potential in Non-Small Cell Lung Cancer and Pancreatic Cancer," <u>Drugs</u> , 54(3): 447-472 (1997).	
	AR	ROTHENBERG et al., "A phase II trial of gemeitabline in patients with 5-FU-refractory pancreas cancer," <u>Ann.</u> Oncol., 7:347-353 (1996).	
	I AS	STEPHENS, C. D., "Gemcitabine: A New Approach to Treating Pancreatic Cancer," Oncol. Nurs. Forum 25(1):87- 93 (1998).	
	I AT	ZISKE ct al., "Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine," Br. J. Cancer. 89:1413-1417 (2003).	

## ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Examiner Signature	/Bahar Schmidtmann/	Date Considered	07/07/2011

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). \*Applicant is unique citation designation.

Substitute for form 1449B/PTO				Complete if Known		
				Application Number	10/588,409	
INFOR	MATION DIS	CLOS	URE	Filing Date	August 3, 2006	
STATEMENT BY APPLICANT				First Named Inventor	Tidmarsh, George	
				Art Unit	1624	
(Use as many sheets as necessary)				Examiner Name	Unassigned	
Sheet	3	of	3	Attorney Docket Number	021305-004010US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, diy and/or country where published.	T²
	I AU	"Threshold Pharmacouticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint", News Release, Threshold Pharmacouticals Inc., February 27, 2007.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /B.S./

Examiner Signature	/Bahar Schmidtmann/	Date 07/07/2011
-----------------------	---------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique oitation designation number (prionan). \*Applicant is unique oitation designation number (prioration). \*Applicant is unique oitation designation number (prioration). \*Applicant is unique oitation designation of the oitation is not of the oitation oitation oitation of the oitation oitatio